HC Wainwright Has Positive Forecast for Nicox Q3 Earnings

Nicox SA (OTCMKTS:NICXF) – Equities research analysts at HC Wainwright lifted their Q3 2025 earnings per share (EPS) estimates for shares of Nicox in a report issued on Wednesday, December 17th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of $0.18 for the quarter, up from their prior forecast of $0.17.

Separately, Zacks Research upgraded shares of Nicox to a “hold” rating in a report on Friday, October 10th. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy”.

Nicox Stock Performance

Shares of OTCMKTS NICXF opened at $0.30 on Thursday. The firm’s 50 day moving average price is $0.30 and its 200-day moving average price is $0.29. Nicox has a 52-week low of $0.25 and a 52-week high of $0.30.

About Nicox

Nicox is a global biopharmaceutical company focused on the research, development and commercialization of innovative treatments for eye diseases. The company’s therapeutic approach centers on nitric oxide–donating compounds and anti-inflammatory agents designed to address glaucoma, ocular surface disorders and allergic eye conditions. With a pipeline spanning pre-clinical to late-stage clinical programs, Nicox aims to bring new modalities to market that target unmet needs in ophthalmology.

The company’s lead commercial product, ZERVIATE® (ciclesonide ophthalmic solution), is indicated for the relief of ocular itching associated with allergic conjunctivitis.